Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.

Zuzana CiernaVera MiskovskaJan RoskaDana JurkovicovaLucia Borszekova PulzovaZuzana SestakovaLenka HurbanovaKatarina MachalekovaMichal ChovanecKatarina RejlekovaDaniela SvetlovskaKatarina KalavskaKarol KajoPavel BabalJozef MardiakThomas A WardMichal MegoMiroslav Chovanec

Published in: BMC cancer (2020)

XPA expression is an additional independent prognostic biomarker for stratifying GCT patients, allowing for improvements in decision-making on treatment for those at high risk of refractoriness or relapse. In addition, it could represent a novel therapeutic target in GCTs.

Keyphrases

germ cell
end stage renal disease
decision making
ejection fraction
newly diagnosed
chronic kidney disease
poor prognosis
prognostic factors
peritoneal dialysis
binding protein
replacement therapy
patient reported